Phase I/II Study of Umbralisib (TGR-1202), Ublituximab (TG-1101), and Pembrolizumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Richter’s Transformation: 5-Year Follow-up

Drug Category: Array
Conference Category: Array
Lead Author: Roeker L, et al.
Published Date: 18/09/2021
Download Link: /wp-content/uploads/2021/09/Roeker-iwCLL-2021-U2-Pembro-updated-9.19.21.pdf
Download Text: Download
Popup Confirmation?:
site-sidebar-layout: default
ast-site-content-layout: default
site-content-style: default
site-sidebar-style: default
theme-transparent-header-meta: default
stick-header-meta: default
astra-migrate-meta-layouts: set
Scroll to Top